Please assess the completion status of the following clinical trial:

Trial Title: Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects older than the minimum legal adult age (country specific);~* Acute symptomatic proximal DVT and/or symptomatic PE confirmed at the site by appropriate diagnostic imaging;~* Able to provide written informed consent~Exclusion Criteria:~* thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE;~* More than 48 hours pre-treatment with anticoagulant therapy prior to randomization;~* Calculated Creatinine clearance (CrCL) \< 30 mL/min;~* significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \>\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN;~* patients with active cancer for whom long term treatment with (LMW) heparin is anticipated;~* active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin or warfarin;~* chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs);~* treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet therapy;~* concurrent treatment with potent P-gp inhibitors;~* subjects with any condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- heparin/edoxaban tosylate (Type: EXPERIMENTAL): None
- heparin/warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).